hexamethylene bisacetamide has been researched along with Dysmyelopoietic Syndromes in 5 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro." | 6.67 | Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. ( Andreeff, M; Ervin, T; Kufe, D; Marks, PA; Michaeli, J; Rifkind, RA; Sogoloff, H; Stone, R; Tong, WP; Young, CW, 1992) |
| "The efficacy of hexamethylene bisacetamide (HMBA), a potent polar-planar solvent which is capable of differentiating leukemias and solid tumors in vitro at clinically achievable concentrations, was studied in 16 patients with severe myelodysplastic syndromes (MDS)." | 3.68 | Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. ( Auerbach, M; Conley, BA; Donehower, RC; Jones, RJ; Rowinsky, EK; Spivak, JL, 1992) |
| "Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro." | 2.67 | Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. ( Andreeff, M; Ervin, T; Kufe, D; Marks, PA; Michaeli, J; Rifkind, RA; Sogoloff, H; Stone, R; Tong, WP; Young, CW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santini, V | 1 |
| Ferrini, PR | 1 |
| Kizaki, M | 1 |
| Koeffler, HP | 1 |
| Andreeff, M | 1 |
| Stone, R | 1 |
| Michaeli, J | 1 |
| Young, CW | 1 |
| Tong, WP | 1 |
| Sogoloff, H | 1 |
| Ervin, T | 1 |
| Kufe, D | 1 |
| Rifkind, RA | 1 |
| Marks, PA | 1 |
| Rowinsky, EK | 2 |
| Conley, BA | 1 |
| Jones, RJ | 2 |
| Spivak, JL | 2 |
| Auerbach, M | 1 |
| Donehower, RC | 2 |
| Burke, PJ | 1 |
| Griffin, CA | 1 |
2 reviews available for hexamethylene bisacetamide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Argin | 1998 |
Differentiation-inducing agents in the treatment of myelodysplastic syndromes.
Topics: Acetamides; Azacitidine; Calcitriol; Drug Therapy, Combination; Humans; Interferons; Myelodysplastic | 1992 |
1 trial available for hexamethylene bisacetamide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
Topics: Acetamides; Adolescent; Adult; Aged; Bone Marrow; Cell Differentiation; Hematopoietic Stem Cells; Hu | 1992 |
2 other studies available for hexamethylene bisacetamide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Topics: Acetamides; Adult; Aged; Algorithms; Cell Division; Depression, Chemical; Drug Administration Schedu | 1992 |
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Topics: Acetamides; Adult; Aged; Bone Marrow; Cell Differentiation; Cell Transformation, Neoplastic; Colony- | 1990 |